Navigation Links
Material in Medical Technology

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... uncertainties and other factors could lead to material differences between the actual future results, ... with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with ...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

... treatment. They have now confirmed an anti-cancer material which they gave the laboratory name, ... specific anti-cancer antibodies. The active material is a biological agent resulting from a ... CEO of CHAI Foundation. The anti-cancer material was clinically tested outside the U.S. by Dr. ...

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

... uncertainties and other factors could lead to material differences between the actual future results, ... third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with ...

Ceremed's OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds

... LOS ANGELES, Feb. 5 /PRNewswire/ -- New polymer material designed to stop bone bleeding in surgery reduces ... expensive and most commonly used bone hemostasis material despite its well-documented side effects: ... infection and the separation of the sternum. The material is used in cardiac, orthopedic, oral, and ...

DuPont Provides Technology for Washington Hospital Center's Emergency Department

... because it is a seamless, easy-to-clean surface material ideally suited for healthcare environments," said ... 193 sheets and 17 sinks made of the solid surface material to this phase of the ER One project. ... high-performing, easy-to-maintain solid surface material that, when properly used or cleaned, does ...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

... study suggest that the elasticity (low stiffness) of Trabecular Metal material may induce a transfer of stresses to the periacetabular bone that more ... seen around traditional acetabular implants." Trabecular Metal material is a structural biomaterial whose cellular architecture resembles bone and ...

Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial

... provide surgeons with greater flexibility to cut, shape and suture the material to fit each patient's needs. Based on available data, Osteotech estimates ... HCT platform, DuraTech is an engineered nano-structure human collagen material that provides a porous scaffold to facilitate cellular in-growth and ...

Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix

... surgeons with the clinical flexibility to cut, shape and suture the material to fit each patient's needs. Based on available data, Osteotech estimates ... technology, DuraTech is an engineered nano-structure human collagen material that provides a porous scaffold for rapid cellular in-growth to facilitate ...

Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows

... wax, a beeswax-based product, is the most commonly used bone hemostasis material despite its well-documented side effects. Numerous studies have indicated ... We are able to custom-manufacture compounds using each OEM proprietary material in combination with the AOC carrier." About The Company: Ceremed, Inc. ...

Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

... in biodefense. The technology supports the practice of inserting genetic material from the disease-causing virus or parasite into a "vehicle" called a vector, which then delivers the immunogenic material directly to the immune system. Most vectors are based on an adenovirus, ...

CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model

... "This data demonstrates the unique potential of the extracellular matrix material in cardiac applications," said Beecher Lewis, President and COO of ... were discovered at Purdue University. The decellularized matrix material serves as a scaffold to allow adjacent tissues to deliver cells and ...

EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream

... since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including ...

Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program

... A/Indonesia/05/2005 avian influenza virus. The VLPs lack viral genetic material and therefore cannot replicate or cause disease. Commenting on the ... vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection ...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

... since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including ...

EpiCept Reports Regulatory Progress on Ceplene(TM)

... since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including ...

Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine

... and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products ...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including ...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this ...

Cyberonics Provides Update on Depression Post-Approval Study

... management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating ...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

... it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown good production yields as well as excellent immunogenicity, even after just a single inoculation. ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... on current assumptions and forecasts made by Daiichi Sankyo group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These ...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based nucleic acid analysis platform that quantitatively measures genetic target material and its variations in a rapid, accurate, and cost efficient manner. SEQUENOM's MassARRAY system facilitates a number of nucleic acid analysis ...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

... disease outcome in these patients. Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine ...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

... Animal tissue implants are subject to calcium deposition and hardening, due to the body's ability to recognize them as foreign. Synthetic material lacks the performance characteristics of tissue and causes an inflammatory response. ECM, however, leads to growth of functional tissue where ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

... Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. The scientific information discussed in this ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

... of other regulatory agencies worldwide that relate to those projects; dependence on the availability and cost of raw materials; dependence on no material interruptions in supply by contract manufacturers of King's products; dependence on King's compliance with FDA and other government regulations that ...

New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%

... rate to 24 months versus a 50% survival rate for the control group rats that were not fed prebiotics. Additionally, the "prebiotic" rats showed material reductions in cholesterol and body weight versus the control group. Significantly, the prebiotic used in the study was oligofructose ...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

... health, mental health and hormonal balance. About Natural Health International Natural Health International was founded in 1997 as a raw material supply business in Sydney, Australia, that today has expanded internationally and merged with a leading research and development company. One of the ...

CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement

... with an audience of their peers through interactive complex case presentations. This forum will encourage open and critical discussion of the material presented, as well as relevant "standards of care." The overriding goal of this meeting is to emphasize the role of critical thinking and clinical ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its ...

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

... changes made in transferring the manufacturing process for Acetavance may result in a lack of comparability between the commercial product and the material used in clinical trials, and that the FDA may require the company to perform additional non-clinical or clinical studies; the potential that the FDA ...

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

... on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These ...

Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers

... to chop up large molecules into smaller control molecules that help regulate the output of many of the 30,000 human genes. The short bits of genetic material it produces during its dicing activities are termed microRNAs. "Prior research showed that the microRNA profiles of cancer cells are different ...

Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan

... immune system supporter. Itochu partners with Optigenex under an Exclusive Supply and Trademark Licensing Agreement to market AC-11(R) bulk material and consumer products containing AC-11(R) under sublicenses in Japan and several other Asian countries. Daniel Zwiren, president and CEO of ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... drug eluting coronary stent. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as absorbable sutures. As with a metallic stent, Abbott's bioabsorbable device is designed to restore ...

Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State

... technologies compare and contrast a specimen's DNA to the DNA of a healthy individual to identify, at a high resolution, extra or missing genetic material in the specimen. These technologies can detect a proportion of additional abnormalities even in patients who have already had extensive cytogenetic ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... eluting coronary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore ...
Other Contents
(Date:8/27/2014)... mastodons, short-faced bears, giant ground sloths, saber-toothed cats ... 13,000 years ago at the end of the Pleistocene ... been debated by scientists who, until recently, could only ... including UC Santa Barbara,s James Kennett, professor emeritus in ... collision with Earth played a major role in the ...
(Date:8/27/2014)... -- Duke University researchers have identified a gene that ... OSCA1, encodes a protein in the cell membrane of ... the plant,s water conservation machinery accordingly. , "It,s ... professor of biology at Duke. , The findings, ... , could make it easier to feed the world,s ...
(Date:8/27/2014)... a new skill is easier when it is related ... trained pianist might learn a new melody more easily ... Neural engineers from the Center for the Neural Basis ... Pittsburgh and Carnegie Mellon Universityhave discovered a fundamental constraint ... Published as the cover story in the Aug. 28, ...
Breaking Biology News(10 mins):Nanodiamonds are forever 2Nanodiamonds are forever 3Water 'thermostat' could help engineer drought-resistant crops 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3
(Date:8/28/2014)... Hastings and Hastings, a Phoenix Arizona ... in the industry is pleased to report having saved ... approximately $125,000. This is exciting news for existing clients ... well defined proof that Hastings and Hastings stands behind ... fees. Saving clients money when it comes to settlements ...
(Date:8/28/2014)... 28, 2014 InventHelp, a ... clients, an inventor from California, has designed an alternative ... invention is patented. , The “Abdominal Swimming Support” is ... risk of injuries from physical activity if one is ... or muscular atrophy. Ideal for use as a ...
(Date:8/28/2014)... Baltimore, MD (PRWEB) August 28, 2014 ... has received Diamond level Allergan Privilege Program status ... widely used treatments as Botox, Juvederm, and Voluma. Maryland ... exemplary and prolific use of these treatments. The dermatologists ... in injectable treatments, and are one of the leading ...
(Date:8/28/2014)... 2014 Altec Products, Inc., a ... announced today that they have been awarded the ... of the International Association of Microsoft Channel Partners ... founded in 1994, providing Microsoft Partners with a ... community at large while facilitating mutual growth and ...
(Date:8/28/2014)... 2014 Dr. Bryan McIntosh of Bellevue, ... guide to the tummy tuck cosmetic procedure, leading ... procedure itself, and how to recover well afterwards. ... Dr. McIntosh also discusses how to have accurate expectations ... the procedure is as successful as possible. , To ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 3Health News:InventHelp® Client Patents “Abdominal Swimming Support” – Invention Could Serve as an Alternative Flotation Device 2Health News:Maryland Laser Skin and Vein Receives Diamond Status From Allergan 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
Other TagsOther Tags